Cancer Targeted Technology received a milestone payment from Advanced Accelerator Applications International S.A. triggered by the upcoming clinical trials of investigational 18F-CTT1057, a diagnostic PET imaging agent for prostate cancer.
[Cancer Targeted Technology (Business Wire, Inc.)]
Sorry, but the selected Zotpress account can't be found.
